 shares hit ms drug suspension shares plunged firms suspended sales new multiple sclerosis drug patient death new stock exchange shares lost partner shed firms took action death central nervous disease suspected case condition cases cited involved use existing multiple sclerosis drug companies reports rare condition progressive patients taking approved use widely tipped world leading multiple sclerosis treatment companies work clinical investigators evaluate patients consult leading experts better understand possible risk firms statement outcome evaluations used determine possible dosing clinical trials future commercial availability analysts believed product provide new growth opportunity faced increased competition rivals biggest firm stock exchange expected receive boost new product inquiry accounts brought group close bankruptcy firm rebuilding price increasing value company hunter stockbrokers question mark finished 18.90 fell 28.63 38.65 shares pharmaceutical firm closed 19.84 151.5 pence stock exchange partner set pull deal experimental disease treatment japan pharmaceutical likely end licensing agreement prompting analysts raise questions level future cash reserves